The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
The two companies have been working together since February and now are formalizing plans to develop and test new products.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.
The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.
The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.
The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.
The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.